Texaphyrins: Synthesis and Development of a Novel Class of Therapeutic Agents

[1]  V. Lynch,et al.  Binding of pyridine and benzimidazole to a cadmium "expanded porphyrin": solution and x-ray structural studies , 1989 .

[2]  S M Marcovina,et al.  Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. , 1999, Circulation.

[3]  S. Springs,et al.  Biomedical applications of lanthanide (III) texaphyrins Lutetium(III) texaphyrins as potential photodynamic therapy photosensitizers , 1997 .

[4]  D. Kessel,et al.  HEMATOPORPHYRIN and HPD: PHOTOPHYSICS, PHOTOCHEMISTRY and PHOTOTHERAPY , 1984, Photochemistry and photobiology.

[5]  J. Sessler,et al.  Preclinical Evaluation of Gadolinium (III) Texaphyrin Complex: A New Paramagnetic Contrast Agent for Magnetic Resonance Imaging , 1994, Investigative radiology.

[6]  R. Redmond,et al.  A Compilation of Singlet Oxygen Yields from Biologically Relevant Molecules , 1999, Photochemistry and photobiology.

[7]  A. Richter,et al.  In vitro AND in vivo UPTAKE OF BENZOPORPHYRIN DERIVATIVE INTO HUMAN AND MINISWINE ATHEROSCLEROTIC PLAQUE , 1993, Photochemistry and photobiology.

[8]  T. Mallouk,et al.  Ground- and excited-state spectral and redox properties of cadmium(II) texaphyrin , 1989 .

[9]  S. Dische.  Keynote address: hypoxic cell sensitizers: clinical developments. , 1989, International Journal of Radiation Oncology, Biology, Physics.

[10]  D. Kessel,et al.  Photodynamic therapy of B16F10 murine melanoma with lutetium texaphyrin. , 1998, Journal of Investigative Dermatology.

[11]  Tran C. Chanh,et al.  Photodynamic inactivation of enveloped viruses using sapphyrin, a 22 pi-electron expanded porphyrin: possible approaches to prophylactic blood purification protocols , 1990, Photonics West - Lasers and Applications in Science and Engineering.

[12]  J. Sessler,et al.  13C and 31P NMR Study of Paramagnetic Lanthanide(III) Texaphyrins , 1995 .

[13]  P. Merkel,et al.  Rate constant for the reaction between 1,3-diphenylisobenzofuran and singlet oxygen , 1975 .

[14]  Kevin M. Smith,et al.  Alkyl Ether Analogs of Chlorophyll‐a Derivatives: Part 1. Synthesis, Photophysical Properties and Photodynamic Efficacy , 1996, Photochemistry and photobiology.

[15]  N. Mikheev,et al.  Complex formation of the lanthanides and actinides in lower oxidation states , 1991 .

[16]  C. Gomer,et al.  Clinical and preclinical photodynamic therapy , 1995, Lasers in surgery and medicine.

[17]  G. Peyman,et al.  Angiographic and histologic effects of fundus photodynamic therapy with a hydrophilic sensitizer (mono-L-aspartyl chlorin e6). , 1999, Ophthalmology.

[18]  David Kessel,et al.  Selective uptake of texaphyrins in atheromatous plaque , 1996, Photonics West.

[19]  M. Berns,et al.  In vitro and in vivo comparison of argon‐pumped and diode lasers for photodynamic therapy using second‐generation photosensitizers , 1998, Lasers in surgery and medicine.

[20]  W. Cheong,et al.  Photoangioplasty: An emerging clinical cardiovascular role for photodynamic therapy. , 2000, Circulation.

[21]  J. Fike,et al.  Toxicology of a Boronated Porphyrin in Dogs , 1999, Photochemistry and photobiology.

[22]  J. Bommer,et al.  PHOTOBLEACHING OF MONO‐l‐ASPARTYL CHLORIN e6 (NPe6): A CANDIDATE SENSITIZER FOR THE PHOTODYNAMIC THERAPY OF TUMORS , 1993, Photochemistry and photobiology.

[23]  B. Pogue,et al.  Photophysical Properties of Tin Ethyl Etiopurpurin I (SnET2) and Tin Octaethylbenzochlorin (SnOEBC) in Solution and Bound to Albumin , 1998, Photochemistry and photobiology.

[24]  Christoph Abels,et al.  Topical application of a first porphycene dye for photodynamic therapy – penetration studies in human perilesional skin and basal cell carcinoma , 1997, Archives of Dermatological Research.

[25]  V. Lynch,et al.  An "expanded porphyrin": the synthesis and structure of a new aromatic pentadentate ligand , 1988 .

[26]  J. McEwan,et al.  Clinical study of adjuvant photodynamic therapy to reduce restenosis following femoral angioplasty , 1999, The British journal of surgery.

[27]  T. Phillips,et al.  A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). , 1991, International journal of radiation oncology, biology, physics.

[28]  T. Mallouk,et al.  Effects of substituents on the spectral and redox properties of cadmium(II) texaphyrins , 1990 .

[29]  R A Miller,et al.  Phototherapy of cancer and atheromatous plaque with texaphyrins. , 1996, Journal of clinical laser medicine & surgery.

[30]  J. Sessler,et al.  One-electron reduction and oxidation studies of the radiation sensitizer gadolinium(III) texaphyrin (PCI-0120) and other water soluble metallotexaphyrins , 1999 .

[31]  Y. Hsiang,et al.  DETERMINING THE OPTIMAL DOSE OF PHOTOFRIN® IN MINISWINE ATHEROSCLEROTIC PLAQUE , 1993, Photochemistry and photobiology.

[32]  T. G. Truscott,et al.  Photophysical properties of 5,10,15,20-tetrakis(m-hydroxyphenyl)porphyrin (m-THPP), 5,10,15,20-tetrakis(m-hydroxyphenyl)chlorin (m-THPC) and 5,10,15,20-tetrakis(m-hydroxyphenyl)bacteriochlorin (m-THPBC): a comparative study , 1999 .

[33]  Fan Qing,et al.  Photoeradication and imaging of atheromatous plaque with texaphyrins , 1997, Photonics West - Biomedical Optics.

[34]  F. Wierrani,et al.  Clinical effect of meso‐tetrahydroxyphenylchlorine based photodynamic therapy in recurrent carcinoma of the ovary: preliminary results , 1997, British journal of obstetrics and gynaecology.

[35]  K Svanberg,et al.  Photodynamic therapy of non‐melanoma malignant tumours of the skin using topical δ‐amino levulinic acid sensitization and laser irradiation , 1994, The British journal of dermatology.

[36]  M. Blumenkranz,et al.  Lutetium texaphyrin (Lu-Tex): a potential new agent for ocular fundus angiography and photodynamic therapy. , 2000, American journal of ophthalmology.

[37]  D. Phillips,et al.  The photochemistry of sensitisers for photodynamic therapy , 1995 .

[38]  B. James,et al.  Porphyrins and Metalloporphyrins: Potential Hypoxic Agents , 1996, Metal-based drugs.

[39]  D. Lankin,et al.  Oxo pyrazoline spiro oxiranes a new class of reactive hetero cycles , 1983 .

[40]  Fan Qing,et al.  Light-emitting diode versus laser irradiation phototherapy with lutetium texaphyrin (PCI-0123) , 1997, Photonics West - Biomedical Optics.

[41]  K König,et al.  Photodynamic activity of liposome‐delivered Cd‐texaphyrin using tumor‐bearing nude mice , 1993, Lasers in surgery and medicine.

[42]  S. Papa,et al.  Reactive oxygen species, mitochondria, apoptosis and aging. , 1997 .

[43]  R. Keck,et al.  New photosensitizers for photodynamic therapy: combined effect of metallopurpurin derivatives and light on transplantable bladder tumors. , 1988, Cancer research.

[44]  S Paulin,et al.  Fluorescence of experimental atheromatous plaques with hematoporphyrin derivative. , 1983, The Journal of clinical investigation.

[45]  K Svanberg,et al.  Photodynamic therapy utilising topical delta-aminolevulinic acid in non-melanoma skin malignancies of the eyelid and the periocular skin. , 1999, Acta ophthalmologica Scandinavica.

[46]  J. Kennedy,et al.  The Monitoring of ALA-Induced Protoporphyrin IX Accumulation and Clearance in Patients with Skin Lesions by In Vivo Surface-Detected Fluorescence Spectroscopy , 1999, Lasers in Medical Science.

[47]  M. Jenkins,et al.  Intra-arterial photodynamic therapy using 5-ALA in a swine model. , 1998, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[48]  J. V. van Lier,et al.  Metal complexes as photo- and radiosensitizers. , 1999, Chemical reviews.

[49]  J. Brown,et al.  Re-evaluating gadolinium(III) texaphyrin as a radiosensitizing agent. , 2000, Cancer research.

[50]  K. Ghiggino,et al.  Photophysics and Intracellular Distribution of a Boronated Porphyrin Phototherapeutic Agent , 1996, Photochemistry and photobiology.

[51]  R. Keck,et al.  New sensitizers for photodynamic therapy: controlled synthesis of purpurins and their effect on normal tissue. , 1989, Journal of medicinal chemistry.

[52]  Jonathan L. Sessler,et al.  Spectroscopy, photokinetics, and cellular effect of far-red and near-infrared absorbing photosensitizers , 1992, Photonics West - Lasers and Applications in Science and Engineering.

[53]  D. Vanel,et al.  Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases. , 1999, Radiology.

[54]  A. Scherz,et al.  Metal-Substituted Bacteriochlorophylls. 1. Preparation and Influence of Metal and Coordination on Spectra , 1998 .

[55]  Jonathan L. Sessler,et al.  Gadolinium(III) texaphyrin : a novel MRI contrast agent , 1993 .

[56]  Kathryn W. Woodburn,et al.  Feasibility of repeated sequential treatments of RIF-1 tumors with photodynamic therapy (PDT) using lutetium texaphyrin (PCI-0123) , 1997, Photonics West - Biomedical Optics.

[57]  M. Berns,et al.  Photodynamic activity of lutetium‐texaphyrin in a mouse tumor system , 1999, Lasers in surgery and medicine.

[58]  M. Kreimer‐Birnbaum,et al.  Modified porphyrins, chlorins, phthalocyanines, and purpurins: second-generation photosensitizers for photodynamic therapy. , 1989, Seminars in hematology.

[59]  Daniel R. Doiron,et al.  SnET2: clinical update , 1996, Photonics West.

[60]  Hans Auler,et al.  Untersuchungen über die Rolle der Porphyrine bei geschwulstkranken Menschen und Tieren , 1942, Zeitschrift für Krebsforschung.

[61]  R. K. Pandey,et al.  Parabolic Quantitative Structure‐Activity Relationships and Photodynamic Therapy: Application of a Three‐Compartment Model with Clearance to the In Vivo Quantitative Structure‐Activity Relationships of a Congeneric Series of Pyropheophorbide Derivatives Used as Photosensitizers for Photodynamic Ther , 1999, Photochemistry and photobiology.

[62]  Julia G. Levy,et al.  Characterization Of Benzoporphyrin Derivative, A New Photosensitizer , 1989, Other Conferences.

[63]  Gupta,et al.  Photodynamic therapy with meso‐tetra(hydroxyphenyl) chlorin in the topical treatment of Bowen's disease and basal cell carcinoma , 1999, The British journal of dermatology.

[64]  M. Mehta,et al.  Phase IB/II trial of the radiation sensitizer gadolinium texaphyrin (Gd-Tex) for patients with brain metastases: Final results , 1998 .

[65]  J. Sessler,et al.  Lutetium Texaphyrin (PCI‐0123): A Near‐Infrared, Water‐Soluble Photosensitizer , 1996, Photochemistry and photobiology.

[66]  T. Dougherty,et al.  HOW DOES PHOTODYNAMIC THERAPY WORK? , 1992, Photochemistry and photobiology.

[67]  V. Lynch,et al.  1H NMR Spectroscopic Study of Paramagnetic Lanthanide(III) Texaphyrins. Effect of Axial Ligation , 1995 .

[68]  Jonathan L. Sessler,et al.  Spectroscopic studies of photosensitization in solutions and in cells , 1995, Other Conferences.

[69]  J. Sessler,et al.  A water-stable gadolinium(III) complex derived from a new pentadentate expanded porphyrin ligand , 1989 .

[70]  J. Kennedy,et al.  Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): mechanisms and clinical results. , 1996, Journal of clinical laser medicine & surgery.

[71]  A. Morgan,et al.  Observations on the synthesis and spectroscopic characteristics of purpurins , 1986 .

[72]  J. Brown,et al.  SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. , 1993, British Journal of Cancer.

[73]  J A Koutcher,et al.  In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. , 1999, International journal of radiation oncology, biology, physics.

[74]  Masoud Panjehpour,et al.  Photodynamic therapy trials with lutetium texaphyrin (Lu-Tex) in patients with locally recurrent breast cancer , 1998, Photonics West - Biomedical Optics.

[75]  H. Pass,et al.  Photodynamic therapy in oncology: mechanisms and clinical use. , 1993, Journal of the National Cancer Institute.

[76]  D I Rosenthal,et al.  A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[77]  D. Kessel,et al.  PORPHYRIN ACCUMULATION BY ATHEROMATOUS PLAQUES OF THE AORTA , 1984, Photochemistry and photobiology.

[78]  J. Spears,et al.  Uptake of hematoporphyrin derivative by atheromatous plaques: studies in human in vitro and rabbit in vivo. , 1986, Journal of the American College of Cardiology.

[79]  J. Wessels,et al.  Photodynamic antitumor agents: beta-methoxyethyl groups give access to functionalized porphycenes and enhance cellular uptake and activity. , 1994, Journal of medicinal chemistry.

[80]  D. Kessel,et al.  Localization and Efficacy Analysis of the Phototherapeutic Lutetium Texaphyrin (PCI‐0123) in the Murine EMT6 Sarcoma Model , 1997, Photochemistry and photobiology.

[81]  F. Eschwège,et al.  First analysis of tumor regression for the European randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas. , 1992, International journal of radiation oncology, biology, physics.

[82]  H. Altermatt,et al.  Photodynamic therapy with mTHPC and polyethylene glycol-derived mTHPC: a comparative study on human tumour xenografts , 1999, British Journal of Cancer.

[83]  P. Grosjean,et al.  Photodynamic therapy for cancer of the upper aerodigestive tract using tetra(m-hydroxyphenyl)chlorin. , 1996, Journal of clinical laser medicine & surgery.

[84]  Jonathan L. Sessler,et al.  Texaphyrins: Synthesis and Applications , 1994 .

[85]  Greta M. Garbo,et al.  Photophysical And Photochemical Properties Of Purpurins , 1989, Other Conferences.

[86]  D. Kessel,et al.  Pharmacokinetics of N-aspartyl chlorin e6 in cancer patients. , 1997, Journal of photochemistry and photobiology. B, Biology.

[87]  N. Bressler.  Reviewers, authors, and editors: balance of power. , 1999, Archives of ophthalmology.

[88]  James L. Matthews,et al.  Tripyrroledimethine-derived ("texaphyrin"-type) macrocycles: potential photosensitizers which absorb in the far-red spectral region , 1991, Photonics West - Lasers and Applications in Science and Engineering.

[89]  A. M. Olsen,et al.  The use of a derivative of hematoporphyrin in tumor detection. , 1961 .

[90]  P. Ogilby,et al.  Chemistry of singlet oxygen. 36. Singlet molecular oxygen (1.DELTA.g) luminescence in solution following pulsed laser excitation. Solvent deuterium isotope effects on the lifetime of singlet oxygen , 1982 .

[91]  Z. Malik,et al.  The binding and photosensitization effects of tetrabenzoporphyrins and texaphyrin in bacterial cells , 1993, Lasers in Medical Science.

[92]  Daniel R. Doiron,et al.  Retention of tin ethyl etiopurpurin (SnET2) by atheromatous plaques: studies in vitro and in vivo rabbit , 1994, Photonics West - Lasers and Applications in Science and Engineering.

[93]  Alexander D. Cross.  Developing a sensitiser from laboratory to a clinical formulation , 1996, European Conference on Biomedical Optics.

[94]  J. Sessler,et al.  SPECTROSCOPY AND PHOTOSENSITIZATION OF SAPPHYRINS IN SOLUTIONS AND BIOLOGICAL MEMBRANES , 1994, Photochemistry and photobiology.

[95]  I. Tannock,et al.  Oxygen diffusion and the distribution of cellular radiosensitivity in tumours. , 1972, The British journal of radiology.

[96]  J. Sessler,et al.  Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[97]  Julia G. Levy,et al.  Clinical status of benzoporphyrin derivative , 1996, European Conference on Biomedical Optics.

[98]  Z. Malik,et al.  Photosensitization by the near-IR-absorbing photosensitizer lutetium texaphyrin: spectroscopic, in vitro and in vivo studies , 1998 .

[99]  W R Greco,et al.  An in vivo quantitative structure-activity relationship for a congeneric series of pyropheophorbide derivatives as photosensitizers for photodynamic therapy. , 1997, Cancer research.

[100]  T. Dougherty,et al.  A brief history of clinical photodynamic therapy development at Roswell Park Cancer Institute. , 1996, Journal of clinical laser medicine & surgery.

[101]  Jonathan L. Sessler,et al.  Influence of Large Metal Cations on the Photophysical Properties of Texaphyrin, a Rigid Aromatic Chromophore , 2000 .

[102]  M. Shenoy,et al.  Chemical radiosensitizers in cancer therapy. , 1992, Cancer investigation.

[103]  S. Dische.  Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy. , 1985, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[104]  R. Boyle,et al.  Structure and Biodistribution Relationships of Photodynamic Sensitizers * , 1996, Photochemistry and photobiology.

[105]  C. Coleman,et al.  Clinical radiosensitization: why it does and does not work. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  L. Grossweiner,et al.  Singlet oxygen generation by photodynamic agents , 1997 .

[107]  J. Brown,et al.  Keynote address: hypoxic cell radiosensitizers: where next? , 1989, International journal of radiation oncology, biology, physics.

[108]  R. Anderson,et al.  TRANSMITTANCE OF NONIONIZING RADIATION IN HUMAN TISSUES * , 1981, Photochemistry and photobiology.

[109]  J D Spikes,et al.  Photosensitizing properties of mono-L-aspartyl chlorin e6 (NPe6): a candidate sensitizer for the photodynamic therapy of tumors. , 1993, Journal of photochemistry and photobiology. B, Biology.

[110]  Z. Malik,et al.  In vivo photodynamic therapy with the new near-IR absorbing water soluble photosensitizer lutetium texaphyrin and a high intensity pulsed light delivery system. , 1997, Journal of photochemistry and photobiology. B, Biology.

[111]  P. Wingo,et al.  Cancer statistics, 1997 , 1997, CA: a cancer journal for clinicians.

[112]  T. Böhm,et al.  Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. , 1999, Circulation.

[113]  T J Dougherty,et al.  A preliminary pharmacokinetic study of intravenous Photofrin in patients. , 1996, Journal of clinical laser medicine & surgery.

[114]  Leonard I. Grossweiner,et al.  Singlet Oxygen Generation by Metallotexaphyrins , 1999 .

[115]  Stephen Stinson.  Unusual Porphyrin Analog Promises Many Applications , 1988 .

[116]  T. Stephenson,et al.  5‐Aminolevulinic Acid Photosensitization of Dysplastic Barrett's Esophagus: A Pharmacokinetic Study , 1999, Photochemistry and photobiology.

[117]  Richard A. Miller,et al.  Influence of drug and light regimens in determining PDT efficacy with lutetium texaphyrin , 1996, Photonics West.

[118]  V. Lynch,et al.  Synthesis and structural characterization of lanthanide(III) texaphyrins , 1993 .

[119]  Stephen B. Kahl,et al.  Synthesis of tetrakis-carborane-carboxylate esters of 2,4-bis-(α,β-dihydroxyethyl)-deuteroporphyrin IX , 1990 .

[120]  T. Mallouk,et al.  Metallotexaphyrins: a new family of photosensitisers for efficient generation of singlet oxygen , 1989 .

[121]  R. Callender,et al.  Light Activates Reduction of Methotrexate by NADPH in the Ternary Complex with Escherichia coli Dihydrofolate Reductase , 1999, Photochemistry and photobiology.

[122]  J C Kennedy,et al.  Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. , 1992, Journal of photochemistry and photobiology. B, Biology.

[123]  J. Kennedy,et al.  Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. , 1990, Journal of photochemistry and photobiology. B, Biology.

[124]  P Baas,et al.  Photodynamic therapy: a promising new modality for the treatment of cancer. , 1996, Journal of photochemistry and photobiology. B, Biology.